References of "LE GOFF, Caroline"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAssessment of high sensitive troponin T and I immunoassays in patients with acute chest
Le Goff, Caroline ULg; Garweg, Christophe ULg; Laurent, Terry et al

in Clinical Chemistry (2010, July), 56(S6), 127

Introduction: Cardiac troponin I and T are specific markers of myocardial injury that are widely used for the diagnosis of acute coronary syndrome (ACS). In acute chest pain without ST-segment elevation ... [more ▼]

Introduction: Cardiac troponin I and T are specific markers of myocardial injury that are widely used for the diagnosis of acute coronary syndrome (ACS). In acute chest pain without ST-segment elevation, they are used to differentiate unstable angina from non ST-segment elevation myocardial infarction (NSTEMI). Recently, troponin assays with higher analytical sensitivities became available to enable the detection of minor myocardial damage and identify individuals at higher risk for ACS. As a result of its high tissue-specificity, cardiac troponin T and I are cardio-specific, highly sensitive markers for myocardial damage. The aim of this study was to evaluate the new higher sensitive troponin (T and I) in patients with stable angina and acute chest pain without ST-segment elevation. Methods: Sixty subjects (mean age : 65.5± 11 years), were included: 20 healthy controls, 20 patients with stable angina, 9 with unstable angina (troponin-) and 18 patients with NSTEMI myocardial infarction (troponin+). The protocol was approved by the ethic committee of the University of Liège (Belgium). High sensitive troponin T (hsTnT) determination was realized on heparin plasma by electrochemiluminescence immunoassay on Modular E (Roche Diagnostic). Troponin I II (TnI II) is a chemiluminescent microparticle immunoassay for the quantitative determination of cardiac troponin-I in heparine plasma on the ARCHITECT i System (Abbott Diagnostic). The lower detection limit of these assays was 0.005μg/L for hsTnT and 0.01μg/L for TnI II. Stastistical analysis was performed using t test. P value <0.05 was considered significant. Results: HsTNT levels were 0.003(0.003, 0.004) [median baseline (1st, 3rd quartile)]ng/ml in controls, 0.0075 (0.00475, 0.014) ng/ml in stable angina, 0.011(0.006, 0.012) ng/ml in unstable angina and 0.3715 (0.1795, 1.00725) ng/ml in NSTEMI ACS. TnI II levels were 0 (0, 0.001) ng/ml in controls and in patients with stable angina, 0.07 (0.005, 0.014) ng/ml in unstable angina and 1.4475 (0.0407, 2.656) ng/ml in NSTEMI. HsTNT and TnI II levels were significantly increased in NSTEMI as compared to control subjects, patients with stable and unstable angina. TnI II levels were also increased in unstable angina as compared to controls. Conclusion: In our population, TnI II was more sensitive than hsTNT to detect minor myocardial damage in patients with unstable angina as compared to controls. Therefore, future studies will have to determine whether TnI II might contribute to better risk stratification and treatment strategy in this group of patients. [less ▲]

Detailed reference viewed: 122 (16 ULg)
Full Text
Peer Reviewed
See detailUse of clinical biology techniques in clinical practice: injections of platelet-rich plasma to heal tendon
Kaux, Jean-François ULg; Le Goff, Caroline ULg; Drion, Pierre ULg et al

in Clinical Chemistry (2010, July), 56(S6), 111

Introduction: A tendon is a tissue which does not heal easily. For example, tendinopathy is a condition which often becomes chronic in the case of bad or overdue management. Several studies, essentially ... [more ▼]

Introduction: A tendon is a tissue which does not heal easily. For example, tendinopathy is a condition which often becomes chronic in the case of bad or overdue management. Several studies, essentially in vitro and, more recently, a few in clinical practice, have demonstrated the positive effects of platelets on the healing process of tendons. A local injection of platelet–rich plasma (PRP), which releases many growth factors, has the potentiality to enhance the tendon healing process. The aim of our experiment was to ascertain whether the use of PRP could accelerate the healing process of an Achilles tendon after a surgically induced lesion. Methods (*): PRP was obtained from the blood of 12 Sprague Dawley rats by cardiac puncture under general anaesthesia until the heart stopped beating. Quantities of 1mL of anticoagulant, adenosine-citrate-dextrose-acid (ACD-A), were added immediately to each 4,5mL of blood. The blood was then centrifuged at 180g for 10 minutes. To improve platelet concentration of the PRP, the supernatant was centrifuged for a second time at 1000g for 10 minutes. The platelets were then collected using a gauge pipette. Cell and platelet counts were made by an auto-analyser. Platelet concentration was around 2.2 to 2.9 x106/mm³. A 5mm defect was surgically induced in the Achilles tendon of 60 rats. Rats were divided into 2 groups of 30: A: a control group (no injection) and B: with a PRP injection. The rats of group B received a PRP injection in situ 1 hour after the surgery on the site of the lesion of the Achilles tendon. Fifty micro-litres of PRP were injected in each rat of the PRP group. Platelets were activated by the local presence of collagen in the wound. Afterwards, the rats of both groups were placed in their cages without immobilization. After 5, 15 and 30 days, 10 rats of each group were euthanized. The traumatized Achilles tendon of each rat was dissected and removed. Immediately after sampling, tendons were submitted to a biomechanical tensile test up to rupture, using a tensile machine with a “Cryo-jaw”. Results: We demonstrated that the force necessary to induce tendon rupture during biomechanical tensile testing was greater for tendons which had been submitted to an injection of PRP. These results were observed and significant (p<0.05) from day 5 onwards. Discussion: This experimentation showed that PRP injections could accelerate the tendon healing process and increase the force needed to break tendons in their healing process. This “accelerating” process can be observed and is significant (p<0.05) as early as day 5. Conclusion: PRP, by the local release of growth factors, would be a new therapeutic tool to accelerate tendon healing. Acknowledgement: This experimentation was partially financed by “Standard de Liège” and “Lejeune-Lechien” grants. (*) All experimental procedures and protocols used in this investigation were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Liège. [less ▲]

Detailed reference viewed: 58 (16 ULg)
Full Text
Peer Reviewed
See detailNew use of VEGF in therapeutics: application in tendon lesions
Kaux, Jean-François ULg; Le Goff, Caroline ULg; Drion, Pierre ULg et al

in Clinical Chemistry (2010, July), 56(S6), 111

Introduction: As demonstrated in previous studies, mechanical overload, injury and inflammation, hypoxic condition or any combination of the above could lead to increased expression of VEGF in the tendon ... [more ▼]

Introduction: As demonstrated in previous studies, mechanical overload, injury and inflammation, hypoxic condition or any combination of the above could lead to increased expression of VEGF in the tendon. Thus, VEGF could participate in the healing of pathological tendons. Indeed, some authors are convinced that this neovascularization is the sign of a chronic tendinopathy while others plead in favour of it being a sign of healing processes. The VEGF111, which is a biologically active and proteolysis-resistant VEGF-A isoform, was recently identified. It is induced by ultraviolet B and genotoxic drugs. Experimentation shows that, in nude mice, tumors formed by HEK293 cells expressing VEGF111 develop a more widespread peritumoral neovascularisation than those expressing other VEGF isoforms. Good angiogenic activity and resistance to proteolysis makes VEGF111 a potential beneficial therapeutic option for ischemic diseases. The aim of our study was to determine whether if VEGF111 could have a therapeutic interest in the framework of tendinous pathology. Methods (*): A 5mm defect was surgically induced in Achilles tendon of 60 rats. Rats were divided into 2 groups of 30: A: a control group (no injection) and B: with a VEGF111 injection. The rats of group B received an injection of 100 ng of VEGF111 in situ 1 hour after surgery on the site of the tendon lesion. Afterwards, rats of both groups were placed in their cages without immobilization. After 5, 15 and 30 days, 10 rats of each group were euthanized. The traumatized Achilles tendon of each rat was dissected and removed. Immediately after sampling, tendons were submitted to a biomechanical tensile test up to rupture, using a tensile machine with “Cryo-jaw”. Statistical analyses were made with an ANOVA. Results: A significant increase over time of the force necessary to induce tendon rupture was observed for tendons which had been submitted to an injection of VEGF111 (p=0.016). The force required to break the tendon is always greater for the VEGF111 group (p<0.05). Discussion: We demonstrated that the force necessary to induce the rupture of a rat’s Achilles tendon during biomechanical tensile testing was greater for tendons which had been submitted to an injection of VEGF111. Thus, this experimentation showed that VEGF111 injections could accelerate the tendon healing process and increase the force needed to break tendons in their healing process. Conclusion: VEGF111 could be a new therapy for tendon lesions. However, other experimentation using a rat model with different concentrations of VEGF111 should be made to ascertain the best concentration for this healing process. Acknowledgement: This experimentation was partially financed by “Standard de Liège” and “Lejeune-Lechien” grants. (*) All experimental procedures and protocols used in this investigation were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Liège. [less ▲]

Detailed reference viewed: 70 (21 ULg)
Full Text
Peer Reviewed
See detailDoes echocardiographic stress test induced release of hsTnT and TnI II?
Le Goff, Caroline ULg; Laurent, Terry; Garweg, Christophe ULg et al

in Clinical Chemistry (2010, July), 56(S6), 128

Background: Cardiac troponins (cTn) are considered as the best biomarkers for detection of myocardial cell injury. In this study, cTnT and cTnI were measured by new commercially available high-sensitive ... [more ▼]

Background: Cardiac troponins (cTn) are considered as the best biomarkers for detection of myocardial cell injury. In this study, cTnT and cTnI were measured by new commercially available high-sensitive methods in patients undergoing brief exercise- or pharmacologicinduced stress. Our aim was to compare cTnT and cTnI levels before and after the stress tests, in the patients with or without reversible ischemia. Materials and Methods: Fifty patients (28 men and 22 women) underwent an echographic stress test (ST) for suspected ischemic heart disease. Of these 50 patients, 28 received pharmacological ST (dobutamine injection) and 22 dynamic ST (bicycle exercise). The patients were subdivided into two groups according to the presence or absence of documented transient reversible ischemia: 14 with reversible ischemia ( mean age: 67.71±9.66 y) and 36 without ischemia ( mean age: 63.17±11.72 y). In all patients, cTnT and cTnI concentrations were measured by high sensitive methods (hsTnT, Roche Diagnostics and TnI II, Abbott Diagnostics) on heparin plasma immediately before (T0) and after ST (T1).The lower detection limit of these assays was 0.005μg/L for hsTnT and 0.01μg/L for TnI II. The protocol was approved by the ethics committee of the University of Liège (Belgium). All patients gave informed consent. All statistical analyses were performed using Medcalc version 8.1 for Windows. P value <0.05 was regarded as statistically significant. Results: There was no significant difference between hsTnT concentrations at T0 and T1, neither in the whole patient group, nor in the subgroups of subjects who received pharmacological ST or dynamic ST. The same was true for TnI II. Although there was no change in hsTnT levels during test in ischemic and in non ischemic patients, the latter tend to demonstrate higher median T0 levels (25th, 75th percentiles) than the others [0.011 (0.007, 0.029) vs 0.007 (0.0047, 0.1125) ng/ml, p=0.09]. They also showed higher median T1 levels [0.014 (0.065, 0.03) vs 0.007 (0.003, 0.0102) ng/ml, p=0.08]. Higher TnI II levels were also recorded in ischemic patients as compared to non ischemic patients at T0[ 0.014 (0.0072; 0.0265) vs 0.005 (0.003; 0.01) ng/ml, p=0.08] and T1[ 0.013 (0.0085- 0.03) vs 0.006 (0.0035-0.008) ng/ml, p=0.08]. Also, TnI II levels did not change during test in both subgroups. Conclusions: Measurement of cardiac troponins by high sensitive methods did not allow to detect significant release of biomarkers from the heart during exercise-or pharmacologic-induced ST, even in patients who demonstrated reversible myocardial ischemia. The type of test – pharmacological or dynamic - was without effect. The patients with induced transient ischemia had however higher troponin T and I levels at baseline, this difference remaining during test. [less ▲]

Detailed reference viewed: 78 (9 ULg)
Full Text
Peer Reviewed
See detailConsequences of laparoscopy on liver ischemia during portal triad clamping in a swine model
Nsadi, Berthier; Pire, E.; Gilson, Nathalie ULg et al

in Acta Chirurgica Belgica (2010, April), 110

Detailed reference viewed: 32 (7 ULg)
Full Text
Peer Reviewed
See detailRelease of cardiac biomarkers after an intense physical exercise: preliminary results
Le Goff, Caroline ULg; Laurent, Terry; Chapelle, Jean-Paul ULg et al

Poster (2010, March 20)

Background: Over the past 2 decades, there has been a large interest in cardiac markers elevations, which are often seen following endurance sport events. These elevations were transient, with levels ... [more ▼]

Background: Over the past 2 decades, there has been a large interest in cardiac markers elevations, which are often seen following endurance sport events. These elevations were transient, with levels decreasing to pre-event concentrations within 24-48 hours. This might be explained by the relatively short half-life of studied markers, or water imbalance during and after the event. Therefore, the present preliminary study aimed to examine the increase in N-terminal pro-brain natriuretic peptide (NT-proBNP), highly sensitivity cardiac troponin T (hsTnT) and I (TnI II), myoglobin, creatine kinase muscle – brain (CK-MB), myeloperoxydase (MPO) and Highly sensitive C-reactive protein (hs-CRP) elevations after prolonged strenuous exercise . Materials and methods: Blood samples (EDTA plasma and heparinised plasma) were drawn at baseline, after 45, 90, 105, 165, 225, 285, 345, 690 and 1440 minutes in two healthy persons (29 year, trained 6 hours per week; 23 year, untrained). Each subjects runs at the maximal possibility during 2 hours. Results: For the untrained person, level of NT-proBNP exceeded the upper reference limits 12 hours after exercise but increased in all times. HsTnT and TnI II levels were upper the reference limit respectively 45 minutes and directly after exercise and increased up to 4 hours after exercise. We reported a decrease of these concentrations above the reference limits after 24 hours. Myoglobin increased after 45 minutes until 5 hours after exercises. It decreased after the 5th hour to be normalized 24 hours after exercise. CK-MB increased directly after the exercise and was upper the reference limits 165 minutes after the exercise. Level of MPO was very high just after exercise and decreased quickly in the following hours to be just upper the limit references 24 hours after exercise. HsCRP levels increased after 105 minutes and continued to increase after 24 hours. For the trained subject, we noted the same profile of increase of cardiac markers levels stayed but in the range of reference. Conclusion: These cases are extremely interesting. Indeed, this observation suggested a physiological counter regulatory process rather a simple increase of myocardial damage related to the intensity of exercise. In fact, for this moment, we do not know if the release of cardiac markers is physiological or pathological thus it must be studied. This preliminary study on endurance training suggested that intensively is determinants of the rate and the magnitude of subsequent cardiac marker release. These results suggested that an adaptation mechanism could exist. Benefits and possible long-term negative aspects of prolonged exercise should be evaluated with a more important population of athletes. [less ▲]

Detailed reference viewed: 46 (11 ULg)
Full Text
Peer Reviewed
See detailComparison between platelet-rich plasma (PRP) and vascular endothelial growth factor-111 (VEGF-111) as a therapeutic tool in tendon healing process
Kaux, Jean-François ULg; Drion, Pierre ULg; Libertiaux, Vincent ULg et al

Poster (2010, March 20)

Introduction In spite of the availability of various treatments for tendinopathy, this pathology often becomes chronic. For this reason, it is of interest to develop new treatments. Among them, the ... [more ▼]

Introduction In spite of the availability of various treatments for tendinopathy, this pathology often becomes chronic. For this reason, it is of interest to develop new treatments. Among them, the injection of platelet-rich plasma (PRP) seems to be a promising one. Indeed, several animal models have demonstrated that injection of blood platelets can initiate and stimulate tendon and ligament repair by releasing growth factors (GF) locally. Among all the GF released by activated platelets, the vascular endothelial growth factor-A (VEGF-A) is known to induce positive effects on vascular function and angiogenesis, and could be implicated in the healing process of tendons. Recently, a novel VEGF-A isoform was identified, the VEGF-111, a biologically active and proteolysis-resistant VEGF-A isoform, also known to present beneficial effects on ischemic diseases. This prompted us to evaluate whether VEFF-111 would have a therapeutic interest within the framework of the tendon pathology. Aim of the study: We hypothesized that the healing of ruptured Achilles tendons, which is the last stage of the Blazina’s classification, could be improved by injection of VEGF-111 that was compared to the potential effect of PRP injections using a rat model. Methods: A 5mm defect was surgically induced in rat Achilles tendon after resection of plantaris tendon. Rats were divided into 3 groups: A: control (no injection), B: PRP treatment and C: VEGF-111 treatment. Rats received a local injection of PRP (50µL) or VEGF-111 (100ng) in situ after the surgery and were placed in their cage without immobilization. After 5, 15 and 30 days, the rats were euthanized in each group. The traumatized Achilles tendon of each rat was removed and dissected during the healing process. Immediately after sampling, tendons were submitted to a biomechanical tensile test up to rupture, using a “Cryo-jaw”. Results: Our results show that developed force necessary to induce tendon rupture during biomechanical tensile test was more important for tendons which had received an injection of PRP or VEGF-111. Moreover, the tensile force necessary to break tendons is higher with PRP than with VEGF-111. These results were already noticed from day 5 onwards. Conclusion: This experimentation has shown that both PRP and VEGF-111 injections stimulated tendon healing process as suggested by the increased force needed to break tendons during its healing process. Furthermore, this acceleration of the cicatrisation process was more significant with PRP than with VEGF-111. This could be explained by the release from platelets of a “cocktail” of growth factors acting in synergy on the healing process. Acknowledgement This experimentation was partially financed by “Standard de Liège 2007” and “Lejeune-Lechien 2008” grants. [less ▲]

Detailed reference viewed: 107 (33 ULg)
Full Text
Peer Reviewed
See detailPlatelet-rich plasma (PRP) increases healing process of rats' Achilles tendons
Kaux, Jean-François ULg; Drion, Pierre ULg; Pascon, Frédéric ULg et al

Conference (2010, March 20)

Introduction Some tendinopathies (epicondylitis, jumper’s knee or Achilles tendinopathy) are frequently considered as rebel to “classic” treatments such as rest, orthotics, NSAIs, electrotherapy ... [more ▼]

Introduction Some tendinopathies (epicondylitis, jumper’s knee or Achilles tendinopathy) are frequently considered as rebel to “classic” treatments such as rest, orthotics, NSAIs, electrotherapy, physiotherapy, corticosteroid infiltrations, extracorporeal shock waves… Recently, several studies, essentially in vitro, demonstrated the positive effects of platelets on the healing process of different tissues: bones, muscles and tendons. Objectives The aim of our experiment was to ascertain whether the use of platelet-rich plasma (PRP) was of interest for accelerating the healing process of Achilles tendon after surgical induced lesion. Methods A 5mm defect was surgically induced in rat Achilles tendon after resection of plantaris tendon. Rats were divided into 2 groups: A: control (no injection) and B: PRP injection. Rats of group B received a PRP injection in situ after the surgery. Afterwards, rats of both groups were placed in their cage without immobilization. After 5, 15 and 30 days, rats were euthanized. The traumatized Achilles tendon of each rat was removed and dissected during this healing process. Immediately after sampling, tendons were submitted to a biomechanical tensile test up to rupture, using a “Cryo-jaw”. Results We demonstrated that the force necessary to induce tendon rupture during biomechanical tensile test study was more important for tendons which had been submitted to an injection of PRP. These results were noticed from day 5 onwards. Discussion – Conclusion This experimentation has shown that PRP injections could accelerate tendons healing process and increase the force needed to break tendons in their healing process. This “accelerating” process can be observed as early as day 5. Acknowledgement This experimentation was partially financed by “Standard de Liège 2007” and “Lejeune-Lechien 2008” grants. [less ▲]

Detailed reference viewed: 130 (36 ULg)
Full Text
Peer Reviewed
See detailGPS™ II and GPS™ III: comparison of obtained platelets concentrations
Kaux, Jean-François ULg; Le Goff, Caroline ULg; Renouf, Julien et al

Poster (2010, March 20)

Introduction: Recently, several researches, essentially in vitro, demonstrated the positive effects of platelets on healing process of different tissues: bones, muscles and tendons. The aim of this study ... [more ▼]

Introduction: Recently, several researches, essentially in vitro, demonstrated the positive effects of platelets on healing process of different tissues: bones, muscles and tendons. The aim of this study is to compare the obtained platelets concentration between the new GPS™ III and GPS™ II. Methods: Two blood samples of 52 mL were taken in 5 volunteers and transferred respectively in both GPS™ II and GPS™ III. These devices were centrifuged at 3200 RPM during 15 min. The platelet-rich plasma (PRP) was thus collected and transferred in 6 mL test tubes. Cells count was done using an analyser ABX Micros 60. Results and conclusion: Platelets concentrations were more important from 6.2 up to 9.2 times with GPS™ II and from 7.3 up to 8.3 times with GPS™ III compared to blood samples. Efficiency of the collected platelets was around 92% for GPS™ II and 96% for GPS™ III. Both techniques made it possible to collect platelets but, unfortunately, also a lot of red and white blood cells. None of these parameters showed any significant difference (p>0.05). Conflicts of interests: The 10 devices GPS™ II and GPS™ III were provided gracefully by the firm Biomet Biologics TTC. [less ▲]

Detailed reference viewed: 91 (16 ULg)
Full Text
Peer Reviewed
See detailComparaison des taux de BNP et de NT-proBNP chez des patients insuffisants rénaux pour prévenir l'insuffisance cardiaque
Le Goff, Caroline ULg; Kaux, Jean-François ULg; Bovy, Christophe ULg et al

in Biotribune Magazine (2010), 34

Background: The aim of the study is to compare the performances of BNP and NT-proBNP for diagnosing heart failure (HF) in a population of patients with high incidence of chronic renal insufficiency (CRI ... [more ▼]

Background: The aim of the study is to compare the performances of BNP and NT-proBNP for diagnosing heart failure (HF) in a population of patients with high incidence of chronic renal insufficiency (CRI, plasma creatinine > 1.5 mg/dl). Patients and methods: Ninety-eight patients were included in this study. BNP and NT-proBNP determinations were performed by an immunofluorescent assay (Biosite®) and by an electrochemiluminescence sandwich immuno assay (Roche Diagnostic®), respectively. Results and discussion: BNP and NTproBNP level are correlated in CRI and non CRI . Both assays are useful to rule out CRI pts suspected of HF. However, in renal failure pts, higher decision limits should be used for improving the positive predictive value of the assays. [less ▲]

Detailed reference viewed: 201 (8 ULg)
Full Text
See detailSport et Biologie Clinique
Le Goff, Caroline ULg; Kaux, Jean-François ULg

Conference (2010, February 11)

Detailed reference viewed: 207 (12 ULg)
Full Text
Peer Reviewed
See detailConsequences of laparoscopy on liver ischemia during portal triad clamping in a swine model
Gilson, Nathalie ULg; Nsadi, Berthier; Pire, E. et al

in Acta Gastro-Enterologica Belgica (2010), 73(1), 13

Detailed reference viewed: 42 (13 ULg)
Full Text
Peer Reviewed
See detailComparaison de 5 techniques de prération du PRP (Platelet-Rich Plasma ou plasma)
Kaux, Jean-François ULg; Le Goff, Caroline ULg; Seidel, Laurence ULg et al

in Annales de Réadaptation et de Médecine Physique (2009, October), 52(Sup. 1), 109

Introduction : Depuis une vingtaine d’années, le développement des activités sportives s’accompagne d’une incidence accrue de diverses tendinopathies, souvent rebelles aux traitements conservateurs ... [more ▼]

Introduction : Depuis une vingtaine d’années, le développement des activités sportives s’accompagne d’une incidence accrue de diverses tendinopathies, souvent rebelles aux traitements conservateurs classiques (anti-inflammatoires non stéroïdiens, orthèses, kinésithérapie, infiltrations…). De nouvelles thérapeutiques, dont l’injection de concentrés plaquettaires (plasma riche en plaquettes ou PRP), sont actuellement en cours d’évaluation clinique. Objectifs : L’injection de PRP fait actuellement l’objet de recherche comme thérapeutique des tendinopathies chroniques. L’injection intra-tendineuse nécessite idéalement un volume minimal afin de diminuer la pression lors de l’injection et minimiser les douleurs, mais il doit également présenter une concentration plaquettaire élevée ; par ailleurs, la quantité de facteurs de croissance libérés pourrait être liée au système de préparation. Méthodes : Après avoir prélevés divers échantillons de sang veineux chez 5 patients, nous avons comparé 5 techniques de préparation du PRP : celle du Service d’Hématologie Biologique du CHU de Liège, le PRP Kit de Curasan®, les techniques Plateltex®, GPS®II et RegenLab®. Résultats : Les différentes techniques permettent d’obtenir des concentrations plaquettaires plus importantes que dans le sang avec des volumes variables (de 0,3 mL à 6 mL) et un nombre de globules rouges et globules blancs limité (sauf pour GPS® II). Le nombre de plaquettes/µL apparaît plus élevé avec la technique Plateltex® et obtient le plus petit volume à injecter. Les autres techniques permettent également d’obtenir de petits volumes sauf avec le GPS®II. Le nombre de plaquettes collectées dans le PRP apparaît donc plus élevé avec cette technique mais avec une concentration faible. Discussion – Conclusion : La technique décrite par Plateltex® permet de recueillir le PRP le plus concentré dans le volume le plus faible. [less ▲]

Detailed reference viewed: 298 (56 ULg)
Full Text
Peer Reviewed
See detailLe PRP (Platelet-Rich Plasma) peut-il favoriser la régénération tendineuse ?
Kaux, Jean-François ULg; Drion, Pierre ULg; Pascon, Frédéric ULg et al

in Annales de Réadaptation et de Médecine Physique (2009, October), 52(Sup. 1), 109-110

Introduction : Certaines tendinopathies (l’épicondylite, la tendinopathie rotulienne supérieure ou encore la tendinopathie d’Achille) demeurent rebelles malgré un traitement « classique » bien conduit ... [more ▼]

Introduction : Certaines tendinopathies (l’épicondylite, la tendinopathie rotulienne supérieure ou encore la tendinopathie d’Achille) demeurent rebelles malgré un traitement « classique » bien conduit : repos, orthèse, AINS, électrothérapie, kinésithérapie, infiltrations de corticoïdes, ondes de choc... Certains travaux, essentiellement in vitro, soulignent les potentialités réparatrices des plaquettes qui présentent la capacité d’accélérer la cicatrisation de différents tissus : os, muscles et tendons. Objectifs : Le but de notre étude préliminaire est d’objectiver l’effet « accélérateur » sur la réparation tendineuse suite à l’emploi d’injection de plasma enrichi en plaquettes (platelet-rich plasma ou PRP) car cette technique pourrait représenter une thérapeutique d’avenir en médecine physique et en traumatologie du sport. Méthodes : Nous avons sectionné et réalisé un défect de 5mm dans le tendon d’Achille de rats (N = 12). Quatre rats ont bénéficié d’une injection in loco de PRP et remis en liberté comme les autres dans leur cage. Trois rats (2 sans PRP et 1 avec PRP) sont euthanasiés à J5, J10, J20 et J30 et le tendon d’Achille en cours de régénération est disséqué et prélevé. Une étude biomécanique de traction jusqu’à rupture est réalisé à l’aide de « Cryo-jaw ». Résultats : L’analyse des résultats montre que la force développée pour obtenir la rupture tendineuse doit être plus importante pour les tendons ayant bénéficié d’une injection de PRP et ce dès J5. Discussion – Conclusion : Cette série préliminaire permet de montrer que les injections de PRP permettent une accélération de la cicatrisation tendineuse et une augmentation des valeurs de résistances à la traction. Une étude avec un plus grand nombre de sujets est en cours. [less ▲]

Detailed reference viewed: 573 (72 ULg)
Full Text
Peer Reviewed
See detailLe cas clinique du mois. Osteogenesis imperfecta
Kaux, Jean-François ULg; Le Goff, Caroline ULg; Debray, François-Guillaume ULg et al

in Revue Médicale de Liège (2009)

We report the case of a young boy who had had multiple bone fractures (more than 10) since the age of 19 months. The father had the same clinical history. The clinical examination was normal for his age ... [more ▼]

We report the case of a young boy who had had multiple bone fractures (more than 10) since the age of 19 months. The father had the same clinical history. The clinical examination was normal for his age except blue sclera. The bone densitometry showed a severe osteoporosis for his age. Biological exam swere correct. The genetic exploration revealed mutation of COL1A2 gene. With this clinical history, the diagnosis of Osteogenesis imperfecta (OI) was retained. OI is a hereditary dystrophy with abnormal synthesis or metabolism of collagen with, often, mutation of COL1A1 or COL1A2 genes. There are 7 different forms. We consider the possible differential diagnoses. The goal of any treatment is to promote bone remineralisation and to decrease the fracture frequency. The treatment includes calcium and vitamin D, and in the presence of some precise criteria, biphosphonate therapy. [less ▲]

Detailed reference viewed: 157 (47 ULg)
Full Text
Peer Reviewed
See detailEvaluation biologique du stress oxydant : application en routine clinique.
Pincemail, Joël ULg; Le Goff, Caroline ULg; Charlier, Corinne ULg et al

in Nutritions & Endocrinologie (2009), Déc

Detailed reference viewed: 123 (28 ULg)
Full Text
Peer Reviewed
See detailComparison of two immunoassays for quantitative measurement of oxydized-LDL
Le Goff, Caroline ULg; Haleng, Jeanine ULg; Chapelle, Jean-Paul ULg

in Immuno-Analyse & Biologie Spécialisée [=IBS] (2009), 24

Detailed reference viewed: 12 (3 ULg)